Zynerba delays genetic disorder drug data on enrollment challenge

New Delhi: Zynerba Pharmaceuticals Inc on Wednesday delayed the timeline for reporting key data from a trial of its cannabis-based drug to treat a rare genetic disorder, citing difficulties in enrolling patients amid a rise in respiratory illnesses. It now expects to present results from the trial in the first half of 2024 and in the second half of 2023.

In October, US doctors had warned that a surge in cases of respiratory syncytial virus (RSV) is coinciding with an increase in COVID transmission and an earlier than normal flu season, raising the specter of a "tripledemic" of respiratory illness this winter.

For the week ended Dec. 10, 4,391 cases of RSV were detected in the United States, according to US Centers for Disease Control and Prevention.